Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Praluent Alirocumab Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete
Repatha evolocumab Primary hyperlipidemia Active
Repatha Evolocumab Primary hyperlipidemia and mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete
Repatha Evolocumab Primary hyperlipidemia; mixed dyslipidemia List with clinical criteria and/or conditions Complete
Oxlumo lumasiran Primary hyperoxaluria type 1 Reimburse with clinical criteria and/or conditions Complete
Ocrevus ocrelizumab Primary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete
Bylvay odevixibat Progressive familial intrahepatic cholestasis (PFIC) Reimburse with clinical criteria and/or conditions Active
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete
Humira Adalimumab Psoriasis List with clinical criteria and/or conditions Complete